Nasdaq · Biotech stocks database

RNA — Atrium Therapeutics Inc.

RNA (Atrium Therapeutics Inc.) stock: $8.34, $142.7M market cap, $263.9M cash, -$121.2M EV, $155.7M fully diluted market cap. Next expected readout: May-28. Lead program: ATR 1072 (Cardiac Glycogenosis), Phase 2. Data from Fully Diluted's biotech stocks database.

What they do

Atrium Therapeutics, Inc. (“the Company,” “Atrium” or “we”) is a clinical-stage biopharmaceutical company focused on developing the delivery of ribonucleic acid (“RNA”) therapeutics to the heart muscle for people living with cardiomyopathies. Atrium’s proprietary technology leverages the RNA delivery platform initially developed at Avidity Biosciences, Inc.

Source: 10-Q FY2026 via SEC EDGAR

Share price

$8.34

Market cap

$142.7M

Cash

$263.9M

Enterprise value

-$121.2M

Balance sheet

Cash	$263.9M
Debt	$0.0M
Net cash	$263.9M
Enterprise value	-$121.2M
Basic shares	17.1M shares
Fully diluted shares	18.7M shares
Fully diluted market cap	$155.7M
Cash per share	$15.43
Quarterly burn	$3.9M
Cash runway	67.2 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

17.1M

Pre-funded warrants

0.0M

Options

1.0M

RSUs

0.4M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.2M

FDSO

18.7M

Cap table as of 2026-06-30.

Price history

Loading RNA daily closes…

Loading price history…

Next catalyst

ATR 1072 · Est. Sep 30, 2027 · half midpoint · guided in 8 mo

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Sep 30, 2027 in 8 mo half midpoint	ATR 1072 Corventis study in PRKAG2 syndrome (initial proof-of-concept data)	Not disclosed	PRKAG2 syndrome ()	2H 2027
Jun 12 - Jul 24 in 19 mo	ATR 1072	Phase 1/2	Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	ATR 1072
Lead indication	Cardiac Glycogenosis
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07738107	Phase 1/2	Not yet recruiting	Sponsor	Atrium Therapeutics	—	Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Atrium Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
DAFNA Capital	128,000	+128,000	0.33%	2026-08-14
ADAR1 Capital Management	57,688	no change	0.04%	2026-08-14
RA Capital Management	0	-864,102	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.

Subscribe to Compounding Ego

RNA — Atrium Therapeutics Inc.

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

RNA — Atrium Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

RNA — Atrium Therapeutics Inc.